ADC Therapeutics faces a precarious financial outlook as its flagship ZYNLONTA franchise struggles to achieve consistent revenue growth, with quarterly figures fluctuating between $16.4M and $23.1M. The company's reliance on debt financing, which surged to $42...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.11+49.1% vs -$0.22 | $19M+1.9% vs $19M |
Q2 2026 May 4, 2026 | -$0.21-10.5% vs -$0.19 | $21M+4.3% vs $20M |
Q2 2026 Mar 10, 2026 | -$0.04+87.5% vs -$0.32 | $23M+3.4% vs $22M |
Q4 2025 Nov 10, 2025 | -$0.30+25.0% vs -$0.40 | $16M-2.2% vs $17M |
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m.
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's commercial performance remained broadly consistent with recent quarters.
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
Benchmark ADCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ADC Therapeutics S.A. (ADCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.31 | $166.62M | -1.17 | 14.85% | -175.31% | — | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $3.80 | $241.54M | -3.22 | 0.78% | -8.7% | -31.27% | — | |
| $265.30 | $468.73B | 111.94 | 8.57% | 9.81% | — | — | |
| $28.17 | $160.55B | 20.71 | -1.65% | 6.81% | 4.87% | — | |
| $1.90 | $143.52K | -0.00 | -82.47% | -140.37% | — | — |
ADC Therapeutics S.A. (ADCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ADC Therapeutics S.A. (ADCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 2, 2026·SEC
Jun 24, 2026·SEC
Get notified when ADCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADC Therapeutics S.A. (ADCT) stock FAQ — growth, dividends, profitability & financials explained
ADC Therapeutics S.A. (ADCT) reported $78.8M in revenue for fiscal year 2025. This represents a 4269% increase from $1.8M in 2017.
ADC Therapeutics S.A. (ADCT) grew revenue by 14.9% over the past year. This is steady growth.
ADC Therapeutics S.A. (ADCT) reported a net loss of $96.9M for fiscal year 2025.
ADC Therapeutics S.A. (ADCT) had negative free cash flow of $102.3M in fiscal year 2025, likely due to heavy capital investments.
